Plain-English translation of NCT05262491 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called to see if it is safe, well-tolerated, and effective for treating people with advanced or hard-to-treat cancers, particularly gastrointestinal cancers and other solid tumors. The study will first determine how much of the medication people can safely receive, and then test whether the treatment shows promise in shrinking tumors or slowing cancer growth.
People with advanced cancers often run out of standard treatment options, and their cancers may continue to grow or spread. This medication is being studied because it may offer a new treatment option for patients whose cancers are no longer responding to conventional therapy.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive the medication as an intravenous infusion during a 3-week cycle. If the medication appears to be helping your cancer and you are tolerating it well, you may continue to receive additional cycles of treatment. Your participation will continue until your cancer progresses, you experience side effects that are too severe to tolerate, or you and your doctor decide to stop for another reason. The study will monitor your safety closely with blood tests and scans to see how your tumor is responding.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China